Vertex Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 25,643,000,000.00 | ROE | 72.79 % |
| Balance Sheet | Total Equity | 18,665,800,000.00 | ROA | 15.42 % |
| Cashflow | Capital Expenditures | -437,600,000.00 | P/FCF | 40.27 |
| Cashflow | Free Cash Flow | 3,193,800,000.00 | – | – |
| Cashflow | Operating Cash Flow | 3,631,400,000.00 | P/CF | 35.42 |
| Income | Earnings per Share (diluted) | 15.32 | Div. Yield | – |
| Income | Net Income | 3,953,200,000.00 | P/E | 32.54 |
| Income | Shares Outstanding | 253,991,224.00 | P/B | 6.89 |
| Income | Total Revenue | 12,001,300,000.00 | P/S | 10.72 |
Ratios calculated on: 10/14/2026
Company Description
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company's two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.vrtx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more